DE60037007D1 - Angereicherte zentralnervensystem-zellpopulationen - Google Patents

Angereicherte zentralnervensystem-zellpopulationen

Info

Publication number
DE60037007D1
DE60037007D1 DE60037007T DE60037007T DE60037007D1 DE 60037007 D1 DE60037007 D1 DE 60037007D1 DE 60037007 T DE60037007 T DE 60037007T DE 60037007 T DE60037007 T DE 60037007T DE 60037007 D1 DE60037007 D1 DE 60037007D1
Authority
DE
Germany
Prior art keywords
cell populations
system cell
central nerve
nerve system
enriched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60037007T
Other languages
English (en)
Other versions
DE60037007T2 (de
Inventor
David W Buck
Nobuko Uchida
Irving Weissman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
StemCells California Inc
Original Assignee
StemCells Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/422,844 external-priority patent/US6468794B1/en
Application filed by StemCells Inc filed Critical StemCells Inc
Publication of DE60037007D1 publication Critical patent/DE60037007D1/de
Application granted granted Critical
Publication of DE60037007T2 publication Critical patent/DE60037007T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
DE60037007T 1999-02-12 2000-02-11 Angereicherte zentralnervensystem-zellpopulationen Expired - Lifetime DE60037007T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US422844 1989-10-17
US11972599P 1999-02-12 1999-02-12
US119725P 1999-02-12
US09/422,844 US6468794B1 (en) 1999-02-12 1999-10-21 Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US16840799P 1999-12-01 1999-12-01
US168407P 1999-12-01
PCT/US2000/003592 WO2000047762A2 (en) 1999-02-12 2000-02-11 Enriched central nervous system cell populations

Publications (2)

Publication Number Publication Date
DE60037007D1 true DE60037007D1 (de) 2007-12-20
DE60037007T2 DE60037007T2 (de) 2008-08-21

Family

ID=46844555

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60037007T Expired - Lifetime DE60037007T2 (de) 1999-02-12 2000-02-11 Angereicherte zentralnervensystem-zellpopulationen
DE60044655T Expired - Lifetime DE60044655D1 (de) 1999-02-12 2000-02-11 Angereicherte Zellpopulationen des zentralen Nervensystems

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60044655T Expired - Lifetime DE60044655D1 (de) 1999-02-12 2000-02-11 Angereicherte Zellpopulationen des zentralen Nervensystems

Country Status (10)

Country Link
US (1) US20070238171A1 (de)
EP (2) EP1900811B1 (de)
JP (2) JP5007003B2 (de)
AT (2) ATE473273T1 (de)
AU (2) AU780256B2 (de)
CA (1) CA2361249C (de)
DE (2) DE60037007T2 (de)
DK (2) DK1144671T3 (de)
ES (2) ES2351170T3 (de)
WO (1) WO2000047762A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
ATE473273T1 (de) * 1999-02-12 2010-07-15 Stemcells California Inc Angereicherte zellpopulationen des zentralen nervensystems
US20050042749A1 (en) 2001-05-16 2005-02-24 Carpenter Melissa K. Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease
GB2379447B (en) 2000-05-17 2004-12-29 Geron Corp Neural progenitor cell populations
US7250294B2 (en) 2000-05-17 2007-07-31 Geron Corporation Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
US20050084963A1 (en) * 2001-06-01 2005-04-21 Tailoi Chan-Ling Purification of lineage-specific cells and uses therefor
AUPR540301A0 (en) * 2001-06-01 2001-06-28 Walter And Eliza Hall Institute Of Medical Research, The A method of purification of cells
ATE371018T1 (de) 2001-06-22 2007-09-15 Stemcells Inc Le-zellen (liver engrafting cells), assays und verwendungen davon
EP1540348A4 (de) * 2002-08-27 2006-10-11 Stemcells California Inc Angereicherte stammzellen- und vorläuferzellpopulationen des zentralen nervensystems und identifizierungs-, isolierungs- und anreicherungsverfahren für solche populationen
JP4481706B2 (ja) * 2004-03-31 2010-06-16 独立行政法人科学技術振興機構 脳梗塞疾患モデルマウス
WO2008064408A1 (en) * 2006-11-27 2008-06-05 The University Of Queensland Generation of enriched populations of neural progenitor cells and their progeny
DK2114167T3 (en) * 2007-01-16 2018-09-17 Univ Rochester NON-HUMAN ANIMALS WITH HUMAN GLIAKIMARY BRAIN
JP5035928B2 (ja) * 2009-12-15 2012-09-26 独立行政法人産業技術総合研究所 ヒト神経幹細胞のスクリーニング方法
JP4997613B2 (ja) * 2009-12-15 2012-08-08 独立行政法人産業技術総合研究所 ヒト神経幹細胞に選択的なモノクローナル抗体及びこれを用いたスクリーニング方法
JP6090735B2 (ja) * 2012-03-02 2017-03-08 国立大学法人山口大学 消化器系がん幹細胞を培養するための無血清培地、及びそれを用いた消化器系がん幹細胞の増殖方法
WO2014125277A1 (en) 2013-02-12 2014-08-21 Reneuron Limited Method of producing microparticles
TWI482782B (zh) * 2013-05-31 2015-05-01 Univ Nat Chiao Tung 架接抗體之雙乳化核殼奈米結構

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
JPH08500245A (ja) * 1992-07-27 1996-01-16 カリフォルニア インスティテュート オブ テクノロジー 哺乳動物の多能性神経幹細胞
IT1264903B1 (it) 1993-06-30 1996-10-17 Sniaricerche S C P A Cristalli liquidi metallo-organici in una matrice polimerica
US5843633A (en) * 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
CA2294737A1 (en) * 1997-07-04 1999-01-14 University Of Utah Research Foundation Neuron-restricted precursor cells
US5968829A (en) * 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
AU2469299A (en) * 1998-01-23 1999-08-09 Cornell Research Foundation Inc. Purified populations of stem cells
US6451306B1 (en) * 1998-04-15 2002-09-17 The Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
EP1117765A2 (de) * 1998-08-31 2001-07-25 New York University Stammzellen mit einem fgf rezeptor auf der zelloberfläche
US6468794B1 (en) * 1999-02-12 2002-10-22 Stemcells, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
ATE473273T1 (de) * 1999-02-12 2010-07-15 Stemcells California Inc Angereicherte zellpopulationen des zentralen nervensystems
US7037719B1 (en) * 1999-02-12 2006-05-02 Stemcells California, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US7105150B2 (en) * 1999-02-12 2006-09-12 Stemcells California, Inc. In vivo screening methods using enriched neural stem cells

Also Published As

Publication number Publication date
EP1144671A2 (de) 2001-10-17
WO2000047762A2 (en) 2000-08-17
US20070238171A1 (en) 2007-10-11
JP2002536023A (ja) 2002-10-29
AU2005202534A1 (en) 2005-07-07
EP1144671B1 (de) 2007-11-07
AU2005202534B2 (en) 2008-05-08
CA2361249A1 (en) 2000-08-17
DE60037007T2 (de) 2008-08-21
WO2000047762A9 (en) 2002-04-11
ATE473273T1 (de) 2010-07-15
ES2295012T3 (es) 2008-04-16
AU780256B2 (en) 2005-03-10
EP1900811B1 (de) 2010-07-07
WO2000047762A3 (en) 2000-12-21
JP5007003B2 (ja) 2012-08-22
DK1144671T3 (da) 2008-03-17
EP1900811A1 (de) 2008-03-19
DE60044655D1 (de) 2010-08-19
AU3361800A (en) 2000-08-29
DK1900811T3 (da) 2010-10-25
CA2361249C (en) 2011-05-10
ES2351170T3 (es) 2011-02-01
JP2010252808A (ja) 2010-11-11
ATE377652T1 (de) 2007-11-15

Similar Documents

Publication Publication Date Title
DE60037007D1 (de) Angereicherte zentralnervensystem-zellpopulationen
WO2005021728A3 (en) Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for these populations
ATE514772T1 (de) Multipotente erwachsene stammzellen und verfahren zu deren isolierung
WO2004020597A3 (en) Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
DE69939945D1 (de) Verfahren zur isolierung von stammzellen
SG152273A1 (en) Pdx1 expressing endoderm
WO2001046384A3 (en) A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
PT1066060E (pt) Celulas estaminais mesenquimais como imunossupressores
GB0127704D0 (en) Nucleic acid enrichment
DE60231035D1 (de) Stammzellen und verfahren zu deren trennung
AU7588101A (en) Ion channel assay methods
TR200000099T1 (tr) Üzüm için yenilenme sistemi ve kullanımı.
FI971168A0 (fi) Keskushermoston toiminnan ja häiriön in vitro -mallit
DE60026729D1 (de) Verfahren zur modifikation von ausgewählten zellen in einer magnetischen zelltrennungsäule
PT877941E (pt) Metodo para enriquecimento em volume de uma populacao ou subpopulacao de celulas
WO2002037944A3 (en) Multiplexed cell analysis system
DE60032508D1 (de) VERFAHREN ZUR VERMEHRUNG VON NATüRLICHEN KILLERZELLEN
EP1687413A4 (de) Verfahren zur differenzierung einer mesenchym-stammzelle zu einer nervenzelle sowie die nervenzelle enthaltende pharmazeutische zusammensetzung gegen eine neurodegenerative krankheit
DE69809561T2 (de) Zusammensetzung und verfahren zur regulierung von zellproliferation und zelltod
EP2377922A3 (de) PDX1-exprimierendes Endoderm
TW200510011A (en) A method for regeneration of bone
DK0750637T3 (da) CAI resistens, som koder for et protein, samt anvendelse deraf
BRPI0407002A (pt) Células cultivadas que apresentam antìgeno cd14+
WO2003004616A3 (en) Dendritic cell isolation methods
ATE329035T1 (de) Cytoplasmische tyrosin kinase

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: STEMCELLS CALIFORNIA, INC., PALO ALTO, CALIF., US

8364 No opposition during term of opposition